$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022004082 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$23.40M	$14.67M	$6.620M
YoY Change	-53.22%	50475.86%	22727.59%
Cost Of Revenue	$481.0K	$254.0K	$308.0K
YoY Change
Gross Profit	$22.92M	$14.41M	$6.312M
YoY Change		49600.0%	21665.52%
Gross Profit Margin	97.94%	98.27%	95.35%
Selling, General & Admin	$44.24M	$44.13M	$43.79M
YoY Change	-53.91%	43.73%	183.42%
% of Gross Profit	193.0%	306.17%	693.69%
Research & Development	$11.15M	$20.07M	$10.09M
YoY Change	-15.35%	63.9%	-8.89%
% of Gross Profit	48.64%	139.22%	159.87%
Depreciation & Amortization	$688.0K	$200.0K	$200.0K
YoY Change	67.8%
% of Gross Profit	3.0%	1.39%	3.17%
Operating Expenses	$56.11M	$65.02M	$53.75M
YoY Change	-3.4%	53.55%	99.89%
Operating Profit	-$32.71M	-$50.35M	-$47.13M
YoY Change	306.17%	19.0%	75.46%
Interest Expense	$109.0K	$106.0K	$142.0K
YoY Change	-92.81%	-37.65%	-55.76%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$32.60M	-$50.25M	-$46.99M
YoY Change	-68.28%	19.22%	77.05%
Income Tax	$726.0K	$8.000K	$18.00K
% Of Pretax Income
Net Earnings	-$33.32M	-$50.26M	-$47.01M
YoY Change	312.71%	19.29%	77.1%
Net Earnings / Revenue	-142.38%	-342.64%	-710.12%
Basic Earnings Per Share	-$0.25	-$0.39	-$0.37
Diluted Earnings Per Share	-$0.25	-$0.39	-$0.37
COMMON SHARES
Basic Shares Outstanding	129.7M shares	128.4M shares	128.2M shares
Diluted Shares Outstanding		128.4M shares	128.2M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$466.1M	$286.4M	$318.7M
YoY Change	17.01%	-26.94%	20.57%
Cash & Equivalents	$231.6M	$57.59M	$121.6M
Short-Term Investments	$234.2M	$228.8M	$197.2M
Other Short-Term Assets	$796.0K	$728.0K	$886.0K
YoY Change	-21.81%	-93.79%	-93.27%
Inventory	$19.33M	$19.29M	$17.38M
Prepaid Expenses	$12.51M	$13.71M	$9.158M
Receivables	$15.41M	$9.814M	$4.418M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$513.3M	$329.2M	$349.7M
YoY Change	22.39%	-18.78%	25.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.418M	$4.551M	$4.813M
YoY Change	-7.69%	-53.1%	-25.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$5.004M
YoY Change	-100.0%	-100.0%
Other Assets	$11.84M	$11.84M	$11.86M
YoY Change	4692.71%	5564.11%	5572.73%
Total Long-Term Assets	$30.04M	$30.85M	$36.58M
YoY Change	-32.08%	-35.36%	137.68%
TOTAL ASSETS
Total Short-Term Assets	$513.3M	$329.2M	$349.7M
Total Long-Term Assets	$30.04M	$30.85M	$36.58M
Total Assets	$543.4M	$360.1M	$386.3M
YoY Change	17.19%	-20.53%	31.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.879M	$3.263M	$2.535M
YoY Change	-84.36%	-83.84%	-81.42%
Accrued Expenses	$32.13M	$27.82M	$24.41M
YoY Change	3977.03%
Deferred Revenue	$190.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.65M	$37.54M	$29.32M
YoY Change	27.03%	54.43%	65.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$16.00M	$16.60M	$16.90M
YoY Change	-1.84%	-14.06%	-5.98%
Total Long-Term Liabilities	$16.00M	$16.60M	$16.90M
YoY Change	-1.84%	-14.06%	-5.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.65M	$37.54M	$29.32M
Total Long-Term Liabilities	$16.00M	$16.60M	$16.90M
Total Liabilities	$64.28M	$61.89M	$54.01M
YoY Change	14.96%	41.88%	51.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$756.1M	-$722.8M	-$672.5M
YoY Change	31.46%
Common Stock	$59.01M	$54.61M	$51.02M
YoY Change	49.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$479.1M	$298.2M	$332.3M
YoY Change
Total Liabilities & Shareholders Equity	$543.4M	$360.1M	$386.3M
YoY Change	17.19%	-20.53%	31.64%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$33.32M	-$50.26M	-$47.01M
YoY Change	312.71%	19.29%	77.1%
Depreciation, Depletion And Amortization	$688.0K	$200.0K	$200.0K
YoY Change	67.8%
Cash From Operating Activities	-$25.92M	-$40.25M	-$37.98M
YoY Change	-909.05%	41.65%	-14.93%
INVESTING ACTIVITIES
Capital Expenditures	-$35.00K	-$63.00K	-$222.0K
YoY Change	-98.4%	-98.65%	-56.13%
Acquisitions
YoY Change
Other Investing Activities	-$5.452M	-$32.74M	$1.892M
YoY Change	-125.56%	-76.59%	-105.85%
Cash From Investing Activities	-$5.487M	-$32.81M	$1.670M
YoY Change	-128.66%	-77.3%	-105.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	205.7M	9.082M	1.279M
YoY Change	16463.77%	-95.2%	-67.0%
NET CHANGE
Cash From Operating Activities	-25.92M	-40.25M	-37.98M
Cash From Investing Activities	-5.487M	-32.81M	1.670M
Cash From Financing Activities	205.7M	9.082M	1.279M
Net Change In Cash	174.3M	-63.97M	-35.03M
YoY Change	638.86%	-491.42%	-52.41%
FREE CASH FLOW
Cash From Operating Activities	-$25.92M	-$40.25M	-$37.98M
Capital Expenditures	-$35.00K	-$63.00K	-$222.0K
Free Cash Flow	-$25.89M	-$40.19M	-$37.76M
YoY Change	-580.55%	69.12%	-14.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36421
CY2021	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4129078
CY2021	dei	City Area Code CityAreaCode	(250)
CY2021	dei	Local Phone Number LocalPhoneNumber	708-4272
CY2021	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2021	dei	Trading Symbol TradingSymbol	AUPH
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1660000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	141653780	shares
CY2021	dei	Auditor Firm AuditorFirmId	271
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Edmonton, Canada
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234178000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15414000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12506000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7171000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	513324000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	419427000	USD
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24380000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11838000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	247000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5383000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q4	us-gaap	Assets Assets	543367000	USD
CY2020Q4	us-gaap	Assets Assets	463661000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6000000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4640000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6412000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1059000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40646000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31997000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15950000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16295000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7680000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	64276000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	55911000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126725000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126725000	shares
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1177051000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	944328000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	59014000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39383000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-852000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-805000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-756122000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575156000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	543367000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463661000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45605000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1091000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	171438000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	95983000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22338000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51139000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50327000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52866000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2098000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1289000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1138000	USD
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-574000	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-6809000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-14919000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	226340000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	154408000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	91261000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-180735000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-104290000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-90943000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	529000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	1516000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	2702000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180206000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88241000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	760000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-47000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181013000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102680000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-88385000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129369000	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118473000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93024000	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	135717000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	223118000	USD
CY2019	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6988000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13748000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7414000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	187732000	USD
CY2020	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6643000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17454000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	196740000	USD
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	365000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23421000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	585000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31243000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-47000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	479091000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2021	us-gaap	Depreciation Depreciation	663000	USD
CY2020	us-gaap	Depreciation Depreciation	82000	USD
CY2019	us-gaap	Depreciation Depreciation	33000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2098000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1289000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1138000	USD
CY2021	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	10000000	USD
CY2020	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	0	USD
CY2019	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31243000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	17454000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	7414000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-903000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9477000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14186000	USD
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	15415000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	300000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	650000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	151000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5644000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13927000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5335000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2559000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1826000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-247000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-106000	USD
CY2020	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	5489000	USD
CY2019	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4076000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13620000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4006000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	332000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8407000	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-157692000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69858000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63585000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	354427000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52108000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7884000	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	438958000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	202951000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2021	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	11838000	USD
CY2020	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	USD
CY2019	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	USD
CY2019	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	6000000	USD
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	297000	USD
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	5584000	USD
CY2019	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	85000	USD
CY2021	us-gaap	Payments For Software PaymentsForSoftware	1198000	USD
CY2020	us-gaap	Payments For Software PaymentsForSoftware	1675000	USD
CY2019	us-gaap	Payments For Software PaymentsForSoftware	0	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	84000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103870000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-158186000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7783000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	196740000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	187732000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	223118000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24007000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6642000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13748000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	365000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6988000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	221112000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194375000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	243854000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40450000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33669000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	188052000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117967000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2021	auph	Legal Settlements Paid LegalSettlementsPaid	0	USD
CY2020	auph	Legal Settlements Paid LegalSettlementsPaid	0	USD
CY2019	auph	Legal Settlements Paid LegalSettlementsPaid	100000	USD
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	749000	USD
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1884000	USD
CY2019	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2619000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	257000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	261000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	59000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231643000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272350000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	306019000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	257000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231900000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates: The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from those estimates.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and short term investments. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as high quality corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss France, Great British Pound and Japanese Yen will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses, including commercial and clinical trial costs are also denominated in U.S. dollars, which mitigates the risk of material foreign exchange fluctuations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company currently has three main customers for the U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 56% and 43% of the Company's total revenues for the year ending December 31, 2021. Two individual customers accounted for 99% of the Company’s net trade accounts receivable balances as of December 31, 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables.</span></div>
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52900000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15400000	USD
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51100000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50300000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	171400000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96000000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22300000	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234200000	USD
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	0	USD
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	19200000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	214900000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	150400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	234178000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	234178000	USD
CY2020Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	150359000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	100000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-47000	USD
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	0	USD
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	234178000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	466078000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	150359000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	422709000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12566000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13927000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4543000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	19326000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13900000	USD
CY2021Q4	auph	Inventory Deposits InventoryDeposits	3900000	USD
CY2021Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	5316000	USD
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	3701000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1632000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2054000	USD
CY2021Q4	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	4762000	USD
CY2020Q4	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	398000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	796000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1018000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12506000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7171000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5254000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4965000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	836000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4418000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2021	us-gaap	Depreciation Depreciation	663000	USD
CY2020	us-gaap	Depreciation Depreciation	82000	USD
CY2019	us-gaap	Depreciation Depreciation	33000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19470000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11066000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8404000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18452000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9120000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6700000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3879000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2635000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8443000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6616000	USD
CY2021Q4	auph	Accrued Research Current AccruedResearchCurrent	4383000	USD
CY2020Q4	auph	Accrued Research Current AccruedResearchCurrent	4185000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18242000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11361000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	34947000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45605000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88241000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318000	USD
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4418000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4786000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-180374000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61024000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-88694000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	168000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41750000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	453000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-180206000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	760000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	144000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	760000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	144000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.254
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	760000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.254
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.024
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.061
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.045
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.218
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.260
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.223
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6126000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5243000	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	120274000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80087000	USD
CY2021Q4	auph	Deferred Tax Assets Expense Share Issue Costs DeferredTaxAssetsExpenseShareIssueCosts	6016000	USD
CY2020Q4	auph	Deferred Tax Assets Expense Share Issue Costs DeferredTaxAssetsExpenseShareIssueCosts	6295000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1086000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2718000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6059000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4808000	USD
CY2021Q4	auph	Deferred Tax Assets Deferred Compensation DeferredTaxAssetsDeferredCompensation	3980000	USD
CY2020Q4	auph	Deferred Tax Assets Deferred Compensation DeferredTaxAssetsDeferredCompensation	4006000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	143541000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103157000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141348000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101792000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2193000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1365000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1356000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1173000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	837000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	192000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2193000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1365000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	39600000	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	429800000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16300000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	288000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	68000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	167000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5383000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1059000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7680000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8739000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8407000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1045000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	653000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	229000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	27000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	3000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	0	USD
CY2021	us-gaap	Lease Cost LeaseCost	1239000	USD
CY2020	us-gaap	Lease Cost LeaseCost	944000	USD
CY2019	us-gaap	Lease Cost LeaseCost	297000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y5M26D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y8M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2019	us-gaap	Short Term Lease Payments ShortTermLeasePayments	0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	646000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	267000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	182000	USD
CY2021	us-gaap	Short Term Lease Payments ShortTermLeasePayments	419000	USD
CY2020	us-gaap	Short Term Lease Payments ShortTermLeasePayments	5804000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1143000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1061000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1085000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1109000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1135000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5638000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11171000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2432000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8739000	USD
CY2021Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21000000	CHF
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	79000000	USD
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111800000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111800000	shares
CY2018Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	15000000	USD
CY2020	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	500	shares
CY2021	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	1700000	shares
CY2021	auph	Warrants Exercised During Period Shares WarrantsExercisedDuringPeriodShares	1700000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141600000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141600000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7591000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.44
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2520000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.00
CY2019	auph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Inducements ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossInducements	1600000	shares
CY2019	auph	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Inducement Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodInducementWeightedAverageExercisePrice	6.28
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3578000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.03
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	311000	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.40
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7822000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.47
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M20D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115655000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7129000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.61
CY2020	auph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Inducements ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossInducements	925000	shares
CY2020	auph	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Inducement Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodInducementWeightedAverageExercisePrice	14.36
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1593000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.39
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	236000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.82
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14047000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.35
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35891000	USD
CY2020Q3	auph	Share Based Compensation Arrangement By Share Based Payment Award Number Of New Employees ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees	105	employee
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2277000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14440
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3238000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13100000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	63300000	USD
CY2020Q4	auph	Share Based Compensation Arrangement By Share Based Payment Award Number Of New Employees ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees	9	employee
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7210
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1012000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13840
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12074000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M9D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	121141000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5849000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.87
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.58
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	24900000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14900000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8500000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	50300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0046
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0055
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0161
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31200000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17500000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31243000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17454000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7414000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19056000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180966000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129369000	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118473000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93024000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15737000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12329000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9513000	shares
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	914000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6620000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14667000	USD
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23404000	USD
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	56109000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50543000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	51457000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	53754000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	65020000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-47134000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-50353000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-32705000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-50379000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-47010000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-33322000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-25932000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26544000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50030000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	27090000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	26892000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	42344000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	58082000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27060000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26863000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42315000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8052000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-8074000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06

Files In Submission

Name	View Source	Status
0001628280-22-004082-index-headers.html	Edgar Link	pending
0001628280-22-004082-index.html	Edgar Link	pending
0001628280-22-004082.txt	Edgar Link	pending
0001628280-22-004082-xbrl.zip	Edgar Link	pending
a2021pwcconsent.jpg	Edgar Link	pending
auph-20211231.htm	Edgar Link	pending
auph-20211231.xsd	Edgar Link	pending
auph-20211231_cal.xml	Edgar Link	unprocessable
auph-20211231_def.xml	Edgar Link	unprocessable
auph-20211231_g1.jpg	Edgar Link	pending
auph-20211231_htm.xml	Edgar Link	completed
auph-20211231_lab.xml	Edgar Link	unprocessable
auph-20211231_pre.xml	Edgar Link	unprocessable
exhibit211listofsubsidiari.htm	Edgar Link	pending
exhibit231consentofindepen.htm	Edgar Link	pending
exhibit311certification302.htm	Edgar Link	pending
exhibit312certification302.htm	Edgar Link	pending
exhibit321certificationsox.htm	Edgar Link	pending
exhibit322certificationsox.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q4 Form 10-K Financial Statement

#000162828022004082 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q4 Form 10-K Financial Statement

#000162828022004082 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph